Urbino Irene, Frairia Chiara, Busca Alessandro, Corcione Silvia, D'Ardia Stefano, Dellacasa Chiara Maria, Giai Valentina, Secreto Carolina, Freilone Roberto, De Rosa Francesco Giuseppe, Aydin Semra, Ciccone Giovannino, Rosato Rosalba, Cerrano Marco, Audisio Ernesta
Department of Oncology, Division of Hematology, Città della Salute e della Scienza, Turin, Italy.
Department of Oncology, SSCVD Trapianto di Cellule Staminali, Città della Salute e della Scienza, Turin, Italy.
Mediterr J Hematol Infect Dis. 2023 Mar 1;15(1):e2023022. doi: 10.4084/MJHID.2023.022. eCollection 2023.
Acute myeloid leukemia (AML) patients are at high risk of infections during post-induction neutropenia. Recently, the role of antibacterial prophylaxis has been reconsidered due to concerns about the emergence of multi-resistant pathogens. The aim of the present study was to evaluate the impact of avoiding prophylaxis on the rate of induction death (primary endpoint), neutropenic fevers, bloodstream infections (BSIs), resistant pathogens BSIs and septic shocks (secondary endpoints).
We performed a retrospective single-center study including 373 AML patients treated with intensive induction chemotherapy, divided into two groups according to levofloxacin prophylaxis given (group A, gA) or not (group B, gB).
Neutropenic fever was observed in 91% of patients in gA and 97% in gB (OR 0.35, IC95% 0.08 - 1.52, p=0162). The rate of BSIs was 27% in gA compared to 34% in gB (OR 0.69, 0.38 - 1.25, p=0.222). The induction death rate was 5% in gA and 3% in gB (OR 1.50, 0.34 - 6.70, p=0.284). Fluoroquinolones (FQ) resistant pathogens were responsible for 59% of total BSIs in gA and 22% in gB (OR 5.07, 1.87 - 13.73, p=0.001); gram-negative BSIs due to multi-drug resistant organisms were 31% in gA and 36% in gB (OR 0.75, 0.15 - 3.70, p=0.727).
Despite its limitations (retrospective nature, single-center, different cohort size), the present study showed that avoiding levofloxacin prophylaxis was not associated with an increased risk of induction death. The cumulative incidence of neutropenic fever was higher in non-prophylaxis group, while no difference was observed for BSIs. In the prophylaxis group we observed a higher incidence of FQ-resistant organisms.
急性髓系白血病(AML)患者在诱导缓解后中性粒细胞减少期间有较高的感染风险。最近,由于担心多重耐药病原体的出现,抗菌预防的作用受到了重新审视。本研究的目的是评估避免预防对诱导死亡发生率(主要终点)、中性粒细胞减少性发热、血流感染(BSIs)、耐药病原体BSIs和感染性休克(次要终点)的影响。
我们进行了一项回顾性单中心研究,纳入了373例接受强化诱导化疗的AML患者,根据是否给予左氧氟沙星预防分为两组(A组,gA;B组,gB)。
gA组91%的患者出现中性粒细胞减少性发热,gB组为97%(OR 0.35,95%置信区间0.08 - 1.52,p = 0.162)。gA组的BSIs发生率为27%,gB组为34%(OR 0.69,0.38 - 1.25,p = 0.222)。gA组的诱导死亡率为5%,gB组为3%(OR 1.50,0.34 - 6.70,p = 0.284)。耐氟喹诺酮(FQ)病原体导致gA组59%的BSIs,gB组为22%(OR 5.07,1.87 - 13.73,p = 0.001);多重耐药菌引起的革兰阴性菌BSIs在gA组为31%,gB组为36%(OR 0.75,0.15 - 3.70,p = 0.727)。
尽管本研究存在局限性(回顾性、单中心、队列规模不同),但结果显示避免使用左氧氟沙星预防与诱导死亡风险增加无关。未进行预防组中性粒细胞减少性发热的累积发生率更高,而BSIs方面未观察到差异。在预防组中,我们观察到FQ耐药菌的发生率更高。